(NASDAQ: EVGN) Evogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 73.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.81%.
Evogene's earnings in 2025 is -$2,749,000.On average, 3 Wall Street analysts forecast EVGN's earnings for 2025 to be -$19,115,087, with the lowest EVGN earnings forecast at -$18,365,476, and the highest EVGN earnings forecast at -$19,677,296. On average, 3 Wall Street analysts forecast EVGN's earnings for 2026 to be -$9,779,812, with the lowest EVGN earnings forecast at -$9,396,290, and the highest EVGN earnings forecast at -$10,067,454.
In 2027, EVGN is forecast to generate -$7,557,127 in earnings, with the lowest earnings forecast at -$7,260,770 and the highest earnings forecast at -$7,779,396.